Directing cancer cells to self-destruct with pro-apoptotic receptor agonists (original) (raw)

• Jemal, A. et al. Cancer statistics, 2008. CA Cancer J. Clin. 58, 71–96 (2008).
  Article PubMed Google Scholar
• Albreht, T., McKee, M., Alexe, D. M., Coleman, M. P. & Martin-Moreno, J. M. Making progress against cancer in Europe in 2008. Eur. J. Cancer 44, 1451–1456 (2008).
  Article PubMed Google Scholar
• Chowdhury, I., Tharakan, B. & Bhat, G. K. Current concepts in apoptosis: the physiological suicide program revisited. Cell. Mol. Biol. Lett. 11, 506–525 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Elmore, S. Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35, 495–516 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Gulbins, E., Jekle, A., Ferlinz, K., Grassme, H. & Lang, F. Physiology of apoptosis. Am. J. Physiol. Renal. Physiol. 279, F605–F615 (2000).
  Article CAS PubMed Google Scholar
• Casella, C. R. & Finkel, T. H. Mechanisms of lymphocyte killing by HIV. Curr. Opin. Hematol. 4, 24–31 (1997).
  Article CAS PubMed Google Scholar
• Rohn, T. T., Head, E., Nesse, W. H., Cotman, C. W. & Cribbs, D. H. Activation of caspase-8 in the Alzheimer's disease brain. Neurobiol. Dis. 8, 1006–1016 (2001).
  Article CAS PubMed Google Scholar
• Sanchez Mejia, R. O. & Friedlander, R. M. Caspases in Huntington's disease. Neuroscientist 7, 480–489 (2001).
  Article CAS PubMed Google Scholar
• Hayakawa, K. et al. Sensitivity to apoptosis signal, clearance rate, and ultrastructure of fas ligand-induced apoptosis in in vivo adult cardiac cells. Circulation 105, 3039–3045 (2002).
  Article CAS PubMed Google Scholar
• Singh, A. B., Kaushal, V., Megyesi, J. K., Shah, S. V. & Kaushal, G. P. Cloning and expression of rat caspase-6 and its localization in renal ischemia/reperfusion injury. Kidney Int. 62, 106–115 (2002).
  Article CAS PubMed Google Scholar
• Prasad, K. V. & Prabhakar, B. S. Apoptosis and autoimmune disorders. Autoimmunity 36, 323–330 (2003).
  Article CAS PubMed Google Scholar
• Gerl, R. & Vaux, D. L. Apoptosis in the development and treatment of cancer. Carcinogenesis 26, 263–270 (2005).
  Article CAS PubMed Google Scholar
• Fan, T. J., Han, L. H., Cong, R. S. & Liang, J. Caspase family proteases and apoptosis. Acta Biochim. Biophys. Sin. (Shanghai) 37, 719–727 (2005).
  Article CAS PubMed Google Scholar
• Lavrik, I. N., Golks, A. & Krammer, P. H. Caspases: pharmacological manipulation of cell death. J. Clin. Invest. 115, 2665–2672 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Thornberry, N. A. Caspases: a decade of death research. Cell Death Differ. 6, 1023–1027 (1999).
  Article CAS PubMed Google Scholar
• Boatright, K. M. et al. A unified model for apical caspase activation. Mol. Cell 11, 529–541 (2003).
  Article CAS PubMed Google Scholar
• Nagata, S. Apoptotic DNA fragmentation. Exp. Cell Res. 256, 12–18 (2000).
  Article CAS PubMed Google Scholar
• Coultas, L. & Strasser, A. The role of the Bcl-2 protein family in cancer. Semin. Cancer Biol. 13, 115–123 (2003).
  Article CAS PubMed Google Scholar
• Letai, A. Pharmacological manipulation of Bcl-2 family members to control cell death. J. Clin. Invest. 115, 2648–2655 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Chinnaiyan, A. M. The apoptosome: heart and soul of the cell death machine. Neoplasia 1, 5–15 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• van Loo, G. et al. The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ. 9, 1031–1042 (2002).
  Article CAS PubMed Google Scholar
• Ashkenazi, A. & Dixit, V. M. Death receptors: signaling and modulation. Science 281, 1305–1308 (1998).
  Article CAS PubMed Google Scholar
• Nagata, S. Apoptosis by death factor. Cell 88, 355–365 (1997).
  Article CAS PubMed Google Scholar
• Peter, M. E. & Krammer, P. H. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 10, 26–35 (2003).
  Article CAS PubMed Google Scholar
• Ashkenazi, A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nature Rev. Cancer 2, 420–430 (2002).
  Article CAS Google Scholar
• Pitti, R. M. et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396, 699–703 (1998).
  Article CAS PubMed Google Scholar
• Clancy, L. et al. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc. Natl Acad. Sci. USA 102, 18099–18104 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Wagner, K. W. et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nature Med. 13, 1070–1077 (2007). This study identifies specific biomarkers that robustly predict sensitivity to rhApo2L/TRAIL across numerous and diverse cancer cell lines.
  Article CAS PubMed Google Scholar
• Feig, C., Tchikov, V., Schutze, S. & Peter, M. E. Palmitoylation of CD95 facilitates formation of SDS-stable receptor aggregates that initiate apoptosis signaling. EMBO J. 26, 221–231 (2007).
  Article CAS PubMed Google Scholar
• Muppidi, J. R. & Siegel, R. M. Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death. Nature Immunol. 5, 182–189 (2004).
  Article CAS Google Scholar
• Lee, K. H. et al. The role of receptor internalization in CD95 signaling. EMBO J. 25, 1009–1023 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Austin, C. D. et al. Death-receptor activation halts clathrin-dependent endocytosis. Proc. Natl Acad. Sci. USA 103, 10283–10288 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Kohlhaas, S. L., Craxton, A., Sun, X. M., Pinkoski, M. J. & Cohen, G. M. Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. J. Biol. Chem. 282, 12831–12841 (2007).
  Article CAS PubMed Google Scholar
• Karin, M. & Lin, A. NF-kB at the crossroads of life and death. Nature Immunol. 3, 221–227 (2002).
  Article CAS Google Scholar
• Micheau, O. & Tschopp, J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114, 181–190 (2003).
  Article CAS PubMed Google Scholar
• Varfolomeev, E. E. & Ashkenazi, A. Tumor necrosis factor: an apoptosis JuNKie? Cell 116, 491–497 (2004).
  Article CAS PubMed Google Scholar
• Letai, A. G. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nature Rev. Cancer 8, 121–132 (2008).
  Article CAS Google Scholar
• Nieminen, A. I., Partanen, J. I., Hau, A. & Klefstrom, J. c-Myc primed mitochondria determine cellular sensitivity to TRAIL-induced apoptosis. EMBO J. 26, 1055–1067 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Igney, F. H. & Krammer, P. H. Death and anti-death: tumour resistance to apoptosis. Nature Rev. Cancer 2, 277–288 (2002).
  Article CAS Google Scholar
• Hollstein, M., et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22, 3551–3555 (1994).
  CAS PubMed PubMed Central Google Scholar
• Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 88, 323–331 (1997).
  Article CAS PubMed Google Scholar
• Ghobrial, I. M., Witzig, T. E. & Adjei, A. A. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 55, 178–194 (2005).
  Article PubMed Google Scholar
• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
  Article CAS PubMed Google Scholar
• Kaufmann, S. H. & Vaux, D. L. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 22, 7414–7430 (2003).
  Article CAS PubMed Google Scholar
• Lowe, S. W., Cepero, E. & Evan, G. Intrinsic tumour suppression. Nature 432, 307–315 (2004).
  Article CAS PubMed Google Scholar
• Bin, L. et al. Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding. J. Biol. Chem. 282, 28189–28194 (2007).
  Article CAS PubMed Google Scholar
• Harada, K. et al. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res. 62, 5897–5901 (2002).
  CAS PubMed Google Scholar
• Russo, A., Terrasi, M., Agnese, V., Santini, D. & Bazan, V. Apoptosis: a relevant tool for anticancer therapy. Ann. Oncol. 17 (Suppl. 7), 115–123 (2006).
  Article Google Scholar
• Viardot, A., Barth, T. F., Moller, P., Dohner, H. & Bentz, M. Cytogenetic evolution of follicular lymphoma. Semin. Cancer Biol. 13, 183–190 (2003).
  Article PubMed Google Scholar
• Kim, M. S., Jeong, E. G., Yoo, N. J. & Lee, S. H. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br. J. Cancer 98, 1533–1535 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Rampino, N. et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275, 967–969 (1997).
  Article CAS PubMed Google Scholar
• Wang, Y., Quon, K. C., Knee, D. A., Nesterov, A. & Kraft, A. S. RAS, MYC, and sensitivity to tumor necrosis factor-a-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 65, 1615–1616 (2005). This paper provides direct evidence that oncogenes can sensitize cells to apoptosis stimulation by a PARA.
  Article CAS PubMed Google Scholar
• Lee, J. M. & Bernstein, A. Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Rev. 14, 149–161 (1995).
  Article CAS PubMed Google Scholar
• Cuello, M. et al. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 61, 4892–4900 (2001).
  CAS PubMed Google Scholar
• Kim, S. H., Ricci, M. S. & El Deiry, W. S. Mcl-1: a gateway to TRAIL sensitization. Cancer Res. 68, 2062–2064 (2008).
  Article CAS PubMed Google Scholar
• Panner, A., Parsa, A. T. & Pieper, R. O. Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme. Expert Rev. Anticancer Ther. 6, 1313–1322 (2006).
  Article CAS PubMed Google Scholar
• Poh, T. W., Huang, S., Hirpara, J. L. & Pervaiz, S. LY303511 amplifies TRAIL-induced apoptosis in tumor cells by enhancing DR5 oligomerization, DISC assembly, and mitochondrial permeabilization. Cell Death Differ. 14, 1813–1825 (2007).
  Article CAS PubMed Google Scholar
• Guo, F. et al. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood 99, 3419–3426 (2002).
  Article CAS PubMed Google Scholar
• Li, L. et al. A small molecule Smac mimic potentiates T. Science 305, 1471–1474 (2004).
  Article CAS PubMed Google Scholar
• Ou, D. et al. Synergistic inhibition of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human pancreatic beta cells by Bcl-2 and X-linked inhibitor of apoptosis. Hum. Immunol. 66, 274–284 (2005).
  Article CAS PubMed Google Scholar
• Ray, S., Bucur, O. & Almasan, A. Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor. Apoptosis 10, 1411–1418 (2005).
  Article CAS PubMed Google Scholar
• Hersh, E. M. et al. Phase II studies of recombinant human tumor necrosis factor-a in patients with malignant disease: a summary of the Southwest Oncology Group experience. J. Immunother. 10, 426–431 (1991).
  Article CAS PubMed Google Scholar
• Grunhagen, D. J., De Wilt, J. H., Graveland, W. J., van Geel, A. N. & Eggermont, A. M. The palliative value of tumor necrosis factor-a-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer 106, 156–162 (2006).
  Article PubMed Google Scholar
• Ogasawara, J. et al. Lethal effect of the anti-Fas antibody in mice. Nature 364, 806–809 (1993).
  Article CAS PubMed Google Scholar
• Walczak, H. et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Med. 5, 157–163 (1999).
  Article CAS PubMed Google Scholar
• Bouralexis, S., Findlay, D. M. & Evdokiou, A. Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis 10, 35–51 (2005).
  Article CAS PubMed Google Scholar
• Kelley, S. K. & Ashkenazi, A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr. Opin. Pharmacol. 4, 333–339 (2004).
  Article CAS PubMed Google Scholar
• Rowinsky, E. K. Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies. Clin. Cancer Res. 10, 4220s–4226s (2004).
  Article CAS PubMed Google Scholar
• Pitti, R. M. et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271, 12687–12690 (1996).
  Article CAS PubMed Google Scholar
• Wiley, S. R. et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673–682 (1995).
  Article CAS PubMed Google Scholar
• Sedger, L. M. et al. IFNg mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J. Immunol. 163, 920–926 (1999).
  CAS PubMed Google Scholar
• Takeda, K. et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nature Med. 7, 94–100 (2001).
  Article CAS PubMed Google Scholar
• Wang, S. & El Deiry, W. S. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22, 8628–8633 (2003).
  Article CAS PubMed Google Scholar
• Hamilton, S. E., Wolkers, M. C., Schoenberger, S. P. & Jameson, S. C. The generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells. Nature Immunol. 7, 475–481 (2006).
  Article CAS Google Scholar
• Huntington, N. D. et al. Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nature Immunol. 8, 856–863 (2007).
  Article CAS Google Scholar
• Janssen, E. M. et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434, 88–93 (2005).
  Article CAS PubMed Google Scholar
• Finnberg, N., Klein-Szanto, A. J. & El Deiry, W. S. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J. Clin. Invest. 118, 111–123 (2008).
  Article CAS PubMed Google Scholar
• Grosse-Wilde, A. et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J. Clin. Invest. 118, 100–110 (2008).
  Article CAS PubMed Google Scholar
• Laguinge, L. M. et al. DR5 receptor mediates anoikis in human colorectal carcinoma cell lines. Cancer Res. 68, 909–917 (2008).
  Article CAS PubMed Google Scholar
• Diehl, G. E. et al. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 21, 877–889 (2004).
  Article CAS PubMed Google Scholar
• Wang, S. & El Deiry, W. S. Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res. 64, 6666–6672 (2004).
  Article CAS PubMed Google Scholar
• Almasan, A. & Ashkenazi, A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14, 337–348 (2003).
  Article CAS PubMed Google Scholar
• Smyth, M. J. et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon g-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193, 661–670 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Wu, G. S. et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genet. 17, 141–143 (1997).
  Article CAS PubMed Google Scholar
• Ashkenazi, A. et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155–162 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Ashkenazi, A., Holland, P. & Eckhardt, S. G. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J. Clin. Oncol. 26, 3621–3630 (2008).
  Article CAS PubMed Google Scholar
• Georgakis, G. V. et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br. J. Haematol. 130, 501–510 (2005).
  Article CAS PubMed Google Scholar
• Guo, Y. et al. A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death. J. Biol. Chem. 280, 41940–41952 (2005).
  Article CAS PubMed Google Scholar
• Ichikawa, K. et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nature Med. 7, 954–960 (2001).
  Article CAS PubMed Google Scholar
• Motoki, K. et al. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin. Cancer. Res. 11, 3126–3135 (2005). Refs. 87–90 demonstrate in vivo anti-tumour activity of agonist antibodies to DR4 or DR5 in xenograft models.
  Article CAS PubMed Google Scholar
• Plummer, R. et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin. Cancer. Res. 13, 6187–6194 (2007).
  Article CAS PubMed Google Scholar
• Pukac, L. et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br. J. Cancer 92, 1430–1441 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Tolcher, A. W. et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J. Clin. Oncol. 25, 1390–1395 (2007).
  Article CAS PubMed Google Scholar
• Zhang, L., Zhang, X., Barrisford, G. W. & Olumi, A. F. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett. 251, 146–157 (2007).
  Article CAS PubMed Google Scholar
• Krammer, P. H., Behrmann, I., Daniel, P., Dhein, J. & Debatin, K. M. Regulation of apoptosis in the immune system. Curr. Opin. Immunol. 6, 279–289 (1994).
  Article CAS PubMed Google Scholar
• Bodmer, J. L., Meier, P., Tschopp, J. & Schneider, P. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J. Biol. Chem. 275, 20632–20637 (2000).
  Article CAS PubMed Google Scholar
• Keane, M. M., Ettenberg, S. A., Nau, M. M., Russell, E. K. & Lipkowitz, S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 59, 734–741 (1999).
  CAS PubMed Google Scholar
• Ashkenazi, A., Herbst, R. S. To kill a tumor cell: the potential of proapoptotic receptor agonists. J. Clin. Invest. 118, 1979–1990 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Hymowitz, S. G. et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol. Cell 4, 563–571 (1999).
  Article CAS PubMed Google Scholar
• Lawrence, D. et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nature Med. 7, 383–385 (2001).
  Article CAS PubMed Google Scholar
• LoRusso, P. et al. First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors. J. Clin. Oncol. Abstr. 25, 3534 (2007).
  Article Google Scholar
• Jo, M. et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nature Med. 6, 564–567 (2000).
  Article CAS PubMed Google Scholar
• Ganten, T. M. et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin. Cancer. Res. 12, 2640–2646 (2006).
  Article CAS PubMed Google Scholar
• Hao, C., et al. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res. 64, 8502–8506 (2004).
  Article CAS PubMed Google Scholar
• Adams, C. et al. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ. 15, 751–761 (2008). This paper reports the X-ray crystal structure of an agonist antibody in complex with a pro-apoptotic receptor, providing insights into the potential mechanisms of apoptosis activation.
  Article CAS PubMed Google Scholar
• Sheridan, J. P. et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277, 818–821 (1997).
  Article CAS PubMed Google Scholar
• Marini, P. Drug evaluation: lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2. Curr. Opin. Mol. Ther. 8, 539–546 (2006).
  CAS PubMed Google Scholar
• Hymowitz, S. G. et al. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 39, 633–640 (2000).
  Article CAS PubMed Google Scholar
• Yu, R., Mandlekar, S., Ruben, S., Ni, J. & Kong, A. N. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells. Cancer Res. 60, 2384–2389 (2000).
  CAS PubMed Google Scholar
• Mitsiades, N., Poulaki, V., Tseleni-Balafouta, S., Koutras, D. A. & Stamenkovic, I. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 60, 4122–4129 (2000).
  CAS PubMed Google Scholar
• Xia, X. X., Shen, Y. L. & Wei, D. Z. Purification and characterization of recombinant sTRAIL expressed in Escherichia coli. Acta Biochim. Biophys. Sin. (Shanghai) 36, 118–122 (2004).
  Article CAS PubMed Google Scholar
• Yao, G. H. et al. Induction of apoptosis by recombinant soluble human TRAIL in Jurkat cells. Biomed. Environ. Sci. 20, 470–477 (2007).
  CAS PubMed Google Scholar
• Mitsiades, C. S. et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98, 795–804 (2001).
  Article CAS PubMed Google Scholar
• Daniel, D. et al. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 110, 4037–4046 (2007). This study demonstrated in vivo synergy between rhApo2L/TRAIL and rituximab against non-Hodgkin's lymphoma xenografts and provided insight into the underlying mechanism.
  Article CAS PubMed Google Scholar
• Kelley, S. K. et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 299, 31–38 (2001).
  CAS PubMed Google Scholar
• Jin, H. et al. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res. 64, 4900–4905 (2004).
  Article CAS PubMed Google Scholar
• Hylander, B. L. et al. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J. Transl. Med. 3, 22 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Pollack, I. F., Erff, M. & Ashkenazi, A. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin. Cancer. Res. 7, 1362–1369 (2001).
  CAS PubMed Google Scholar
• Roth, W. et al. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem. Biophys. Res. Commun. 265, 479–483 (1999).
  Article CAS PubMed Google Scholar
• Cuello, M., Ettenberg, S. A., Nau, M. M. & Lipkowitz, S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol. Oncol. 81, 380–390 (2001).
  Article CAS PubMed Google Scholar
• El Zawahry, A., McKillop, J. & Voelkel-Johnson, C. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer 5, 2 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Frese, S. Brunner, T., Gugger, M., Uduehi, A. & Schmid, R. A. Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein. J. Thorac. Cardiovasc. Surg. 123, 168–174 (2002).
  Article CAS PubMed Google Scholar
• Gliniak, B. & Le, T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res. 59, 6153–6158 (1999).
  CAS PubMed Google Scholar
• Lacour, S. et al. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res. 61, 1645–1651 (2001).
  CAS PubMed Google Scholar
• Mizutani, Y., Yoshida, O., Miki, T. & Bonavida, B. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells. Clin. Cancer. Res. 5, 2605–2612 (1999).
  CAS PubMed Google Scholar
• Xiang, H. et al. Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors. Oncogene 21, 3611–3619 (2002).
  Article CAS PubMed Google Scholar
• Nimmanapalli, R. et al. Pretreatment with paclitaxel enhances Apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 61, 759–763 (2001).
  CAS PubMed Google Scholar
• Odoux, C. & Albers, A. Additive effects of TRAIL and paclitaxel on cancer cells: implications for advances in cancer therapy. Vitam. Horm. 67, 385–407 (2004).
  Article CAS PubMed Google Scholar
• Ravi, R. et al. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res. 64, 9105–9114 (2004).
  Article CAS PubMed Google Scholar
• Ray, S. & Almasan, A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res. 63, 4713–4723 (2003).
  CAS PubMed Google Scholar
• Vignati, S., Codegoni, A., Polato, F. & Broggini, M. Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs. Eur. J. Cancer 38, 177–183 (2002).
  Article CAS PubMed Google Scholar
• Ricci, M. S. et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 12, 66–80 (2007).
  Article CAS PubMed Google Scholar
• Hyer, M. L. et al. Synthetic triterpenoids cooperate with tumor necrosis factor related apoptosis inducing ligand to induce apoptosis of breast cancer cells. Cancer Res. 65, 4799–4808 (2005).
  Article CAS PubMed Google Scholar
• Naka, T. et al. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res. 62, 5800–5806 (2002).
  CAS PubMed Google Scholar
• Meng, X. W. et al. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43–9006)-induced TRAIL sensitization. J. Biol. Chem. 82, 29831–29846 (2007).
  Article CAS Google Scholar
• Rosato, R. R., Almenara, J. A., Coe, S. & Grant, S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res. 67, 9490–9500 (2007).
  Article CAS PubMed Google Scholar
• Shankar, S. et al. The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice. Int. J. Oncol. 24, 1133–1114 (2004).
  CAS PubMed Google Scholar
• Shankar, S., Singh, T. R. and Srivastava, R. K. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. Prostate 61, 35–49 (2004).
  Article CAS PubMed Google Scholar
• Fulda, S., Wick, W., Weller, M. & Debatin, K. M. Smac agonists sensitize for Apo2L/T. Nature Med. 8, 808–815 (2002).
  Article CAS PubMed Google Scholar
• Brooks, A. D. et al. The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis. Ann. NY Acad. Sci. 1059, 160–167 (2005).
  Article CAS PubMed Google Scholar
• Johnson, T. R. et al. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 22, 4953–4963 (2003).
  Article CAS PubMed Google Scholar
• Zhu, H. et al. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Cancer Biol. Ther. 4, 781–786 (2005).
  Article CAS PubMed Google Scholar
• Nakata, S. et al. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23, 6261–6271 (2004).
  Article CAS PubMed Google Scholar
• Kelley, R. F. et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J. Biol. Chem. 280, 2205–2212 (2005).
  Article CAS PubMed Google Scholar
• Eggert, A. et al. Resistance to TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Med. Pediatr. Oncol. 35, 603–607 (2000).
  Article CAS PubMed Google Scholar
• LeBlanc, H. N. & Ashkenazi, A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10, 66–75 (2003).
  Article CAS PubMed Google Scholar
• Fulda, S., Meyer, E. & Debatin, K. M. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 21, 2283–2294 (2002).
  Article CAS PubMed Google Scholar
• Jonsson, G., Paulie, S. & Grandien, A. High level of cFLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells. Anticancer Res. 23, 1213–1218 (2003).
  PubMed Google Scholar
• Ullenhag, G. J. et al. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin. Cancer. Res. 13, 5070–5075 (2007).
  Article CAS PubMed Google Scholar
• Zhang, L. & Fang, B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 12, 228–237 (2005).
  Article CAS PubMed Google Scholar
• Ricci, M. S. et al. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol. Cell Biol. 24, 8541–8555 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Baritaki, S. et al. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. J. Immunol. 179, 5441–5453 (2007).
  Article CAS PubMed Google Scholar
• Rahman, M., et al. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res. Treat 12 Feb 2008 [Epub ahead of print].
• Herbst, R. S. et al. A Phase I safety and pharmacokinetic study in patients with advanced cancer treated with recombinant Apo2L/TRAIL, an apoptosis-inducing protein. J. Clin. Oncol. Abstr. 24, 3013 (2006).
  Article CAS Google Scholar
• Fanale, M., et al. Results of a phase Ib study of recombinant human Apo2L/TRAIL with rituximab in patients with relapsed, low-grade NHL. Ann. Oncol. Abstr. 19 (Suppl 4), iv161 (2008).
  Google Scholar
• Soria, J. et al. Phase Ib study of recombinant human (rh)Apo2L/TRAIL in combination with paclitaxel, carboplatin, and bevacizumab (PCB) in patients (pts) with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. Abstr. 26 (Suppl.), 3539 (2008).
  Article Google Scholar
• Jin, H. et al. Cooperation of the agonistic DR5 antibody Apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin. Canc. Res. (in the press)
• Hotte, S. J. et al. A Phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin. Cancer. Res. 14, 3450–3455 (2008).
  Article CAS PubMed Google Scholar
• Chow, L. Q. et al. HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: Results of a phase 1 and PK study. J. Clin. Oncol. Abstr. 24 (Suppl. 18), 2515 (2006).
  Google Scholar
• Oldenhuis, C., et al. A phase I study with the agonistic TRAIL-R1 antibody, mapatumumab, in combination with gemcitabine and cisplatin. J. Clin. Oncol. Abstr. 26 (Suppl.), 3540 (2008).
  Article Google Scholar
• Younes, A., Vose, J. M. & Zelenetz, A. D. Results of a Phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (ETR1-HM01). Blood Abstr. 106, 489 (2005).
  Google Scholar
• Kanzler, S., Trarbach, T., Heinemann, V., Koehne, C. H. & Seeber, S. Results of a Phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed or refractory colorectal cancer (CRC). Abstract 630. 13th European Cancer Conference, Paris, France October 30–November 3, 2005.
  Google Scholar
• Bonomi, P. et al. Results of a Phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/recurrent non-small cell lung cancer. Abstract 1851. 11th World Conference on Lung Cancer, Barcelona, Spain July 3–6. 2005.
  Google Scholar
• Patnaik, A. et al. HGS-ETR2 - A fully human monoclonal antibody to TRAIL-R2: Results of a phase I trial in patients with advanced solid tumors. J. Clin. Oncol. 24 (Suppl. 18), 3012 (2006).
  Google Scholar
• Sikic, B. I. et al. A Phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI. J. Clin. Oncol. 25 (Suppl. 18), 14006 (2007).
  Google Scholar
• Camidge, D. R. et al. A phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer. J. Clin. Oncol. Abstr. 25 (Suppl Suppl. 18), 3582 (2008).
  Google Scholar
• Sharma, S. et al. Phase I trial of LBY135, a monoclonal antibody agonist to DR5, alone and in combination with capecitabine in advanced solid tumors. J. Clin. Oncol. Abstr. 26 (Suppl.), 3538 (2008).
  Article Google Scholar
• Saleh, M. N. et al. A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas. J. Clin. Oncol. Abstr. 26 (Suppl.), 3537 (2008).
  Article Google Scholar
• Levine, A. J. et al. The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br. J. Cancer 69, 409–416 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Vousden, K. H. & Lu, X. Live or let die: the cell's response to p53. Nature Rev. Cancer 2, 594–604 (2002).
  Article CAS Google Scholar
• Datta, S. R. et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231–241 (1997).
  Article CAS PubMed Google Scholar
• Sharp, D. A., Lawrence, D. A. & Ashkenazi, A. Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J. Biol. Chem. 280, 19401–19409 (2005).
  Article CAS PubMed Google Scholar
• Thome, M. & Tschopp, J. Regulation of lymphocyte proliferation and death by FLIP. Nature Rev. Immunol. 1, 50–58 (2001).
  Article CAS Google Scholar
• El Deiry, W. S. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ. 8, 1066–1075 (2001).
  Article CAS PubMed Google Scholar
• Eskes, R., Desagher, S., Antonsson, B. & Martinou, J. C. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol. Cell Biol. 20, 929–935 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Wei, M. C. et al. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 14, 2060–2071 (2000).
  CAS PubMed PubMed Central Google Scholar